RxDoctor Payments Data

Vikas Jindal, MD

Interventional Cardiology · Rochester, NYNPI 1033126321

Payments from drug & device makers

$7,084in general payments, 2019–2025

Across 337 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$969
  • Amgen$847
  • E.r. Squibb & Sons, L.L.C.$710
  • Merck$585
  • Novo Nordisk$544
  • Regeneron Healthcare Solutions, Inc.$379
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$7,084100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,084 in reported general payments places this provider in the 40th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$634,678
Medicare patients
584
Services billed
3,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban319$360,154
EntrestoSacubitril/Valsartan188$220,623
XareltoRivaroxaban148$138,858
JardianceEmpagliflozin114$119,094
Repatha SureclickEvolocumab86$98,305
MounjaroTirzepatide63$84,746
OzempicSemaglutide67$82,726
FarxigaDapagliflozin Propanediol71$74,627
Praluent PenAlirocumab47$46,998
Eplerenone97$6,909
Ezetimibe297$6,088
Atorvastatin Calcium497$5,767
Metoprolol Succinate425$5,746
Ranolazine ErRanolazine44$5,645
Midodrine Hcl19$3,154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$254$360,154319 claims
NovartisEntresto$969$220,623188 claims
Johnson & JohnsonXarelto$320$138,858148 claims
Boehringer IngelheimJardiance$211$119,094114 claims
Lilly USA, LLCMounjaro$44$84,74663 claims
Novo NordiskOzempic$544$82,72667 claims
AstraZenecaFarxiga$343$74,62771 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →